Company news

DiaMedica Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

October 8, 2024

DiaMedica Therapeutics Upcoming Conference Participation

September 3, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

August 6, 2024

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

July 31, 2024

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

July 10, 2024

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

June 30, 2024

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

June 25, 2024

DiaMedica Therapeutics Announces $11.8 Million Private Placement

June 25, 2024

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 7, 2024

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

May 1, 2024

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

April 16, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

March 18, 2024

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

January 28, 2024

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

January 21, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

November 12, 2023

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

November 8, 2023

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

November 5, 2023

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

September 11, 2023

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

September 5, 2023

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

August 13, 2023

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

August 7, 2023

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

July 17, 2023

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

June 20, 2023

DiaMedica Therapeutics Announces $37.5 Million Private Placement

June 20, 2023

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

May 29, 2023

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

May 14, 2023

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

May 7, 2023

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

April 10, 2023

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

March 27, 2023

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

March 19, 2023

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 12, 2023

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

March 5, 2023

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

November 8, 2022

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

November 6, 2022

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

October 30, 2022

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

October 25, 2022

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

September 13, 2022

DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

September 5, 2022

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

August 9, 2022

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

August 3, 2022

DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

July 31, 2022

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

July 5, 2022

DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

May 24, 2022

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

May 3, 2022

DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

April 27, 2022

DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

March 13, 2022

DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

March 7, 2022

DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

February 1, 2022

DiaMedica Therapeutics to Present Research at International Stroke Conference

January 24, 2022

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

January 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.